When did Purple Biotech's stock split?

Purple Biotech shares reverse split on Saturday, August 22nd 2020. The 1-10 reverse split was announced on Friday, August 21st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 21st 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Purple Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Purple Biotech investors own include Biocept (BIOC) , Sorrento Therapeutics (SRNE) , T2 Biosystems (TTOO) , Southwestern Energy (SWN) , VBI Vaccines (VBIV) , Onconova Therapeutics (ONTX) , Advanced Micro Devices (AMD) , Vaxart (VXRT) , Amarin (AMRN) and Citius Pharmaceuticals (CTXR) .

When did Purple Biotech IPO?

Purple Biotech (KTOV) raised $13 million in an initial public offering on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

NASDAQ:KTOV

Purple Biotech (KTOV) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free KTOV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.41
▼
$0.47
50-Day Range: $3.81
▼
$4.94
52-Week Range: $2.20
▼
$14.40

Volume: 279,595 shs
Average Volume: 1.18 million shs
Market Capitalization: $6.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Social Media

Get Purple Biotech alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Purple Biotech Stock (NASDAQ:KTOV)

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

KTOV Stock News Headlines

March 6, 2024 | markets.businessinsider.com

Promising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancements

November 21, 2023 | benzinga.com

Purple Biotech: Q3 Earnings Insights

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

November 21, 2023 | msn.com

Purple Biotech GAAP EPS of -$0.23

October 30, 2023 | msn.com

Purple Biotech files to sell 4.65M ADS for holders

August 25, 2023 | benzinga.com

Alukovinyl Provides Customised And Innovative Purple Car Wrap Films For Car Owners Worldwide

August 24, 2023 | benzinga.com

Purple Biotech Stock (NASDAQ:PPBT), Earnings Estimates, EPS, and Revenue

August 22, 2023 | benzinga.com

Purple Biotech Reports Second Quarter 2023 Financial Results

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

July 19, 2023 | seekingalpha.com

PPBT Purple Biotech Ltd.

July 9, 2023 | latimes.com

Purple Carrot Discount Codes

June 29, 2023 | reuters.com

Purple Promo Codes 2023

May 17, 2023 | markets.businessinsider.com

Purple Biotech (PPBT) Receives a Buy from H.C. Wainwright

March 24, 2023 | seekingalpha.com

Purple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEO

September 9, 2022 | finance.yahoo.com

Rapidly Growing Purple Brands Announces New Director of Winemaking

August 12, 2022 | finance.yahoo.com

‘Purple Hearts’ Star Sofia Carson and Director Elizabeth Allen Rosenbaum Defend Netflix Film After Backlash: ‘Our Intentions Are Very Pure’

July 14, 2022 | marketwatch.com

Purple Biotech Names Efron CEO as Israel Steps Down >PPBT

June 2, 2022 | yahoo.com

Biotech company says woman received 3D printed ear made from her own cells

May 12, 2022 | finance.yahoo.com

Purple Biotech Reports First Quarter 2022 Financial Results

See More Headlines

Receive KTOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KTOV
CUSIP: N/A
CIK: 1614744
Web: www.kitovpharma.com
Phone: 972-3933-3121
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.22
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1 million
Price / Sales: 6.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.56 per share
Price / Book: 0.08

Miscellaneous

Outstanding Shares: 15,725,000
Free Float: N/A
Market Cap: $6.83 million
Optionable: Not Optionable
Beta: 2.37

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Isaac Israel (Age 42)
CEO & Director
Comp: $564.48k
Mr. Gil Efron CPA (Age 54)
Deputy CEO & CFO
Comp: $356.91k
Mr. Avraham Shlomo Ben-Tzvi (Age 49)
Group Chief Legal Officer, Gen. Counsel & Corp. Sec.
Mr. Simcha Rock CPA (Age 70)
M.B.A., CPA, MBA, Strategic Advisor & Director
Dr. Bertrand C. Liang (Age 57)
Chief Medical Officer
Dr. Michael Schickler (Age 62)
Head of Clinical Operations

Key Competitors

View All Competitors

KTOV Stock Analysis - Frequently Asked Questions

When did Purple Biotech's stock split?: Purple Biotech shares reverse split on Saturday, August 22nd 2020. The 1-10 reverse split was announced on Friday, August 21st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 21st 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Purple Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Purple Biotech investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Southwestern Energy (SWN), VBI Vaccines (VBIV), Onconova Therapeutics (ONTX), Advanced Micro Devices (AMD), Vaxart (VXRT), Amarin (AMRN) and Citius Pharmaceuticals (CTXR).
When did Purple Biotech IPO?: Purple Biotech (KTOV) raised $13 million in an initial public offering on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

This page (NASDAQ:KTOV) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Purple Biotech (KTOV) Stock Price, News & Analysis

About Purple Biotech Stock (NASDAQ:KTOV)

KTOV Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

KTOV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info